Try our Advanced Search for more refined results

Pfizer Inc. et al v. Sandoz Inc., et al

  1. April 20, 2016

    Sandoz Loses Bid To Invalidate IP In Toviaz Row With Pfizer

    A Delaware federal judge on Wednesday upheld the validity of five patents licensed by Pfizer Inc. protecting its Toviaz overactive-bladder treatment, dealing a blow to Sandoz Inc. and other drug companies accused of infringement in Pfizer's consolidated suit.

  2. August 12, 2015

    Sandoz Aims to Amend Validity Ruling In Pfizer's Toviaz Suit

    Several drug companies including Sandoz Inc. want a Delaware federal judge to amend his judgment directed after a trial that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz is not invalid as indefinite.

  3. July 23, 2015

    Pfizer Patent Not Indefinite In Sandoz IP Row, Judge Says

    A Delaware federal judge ruled Wednesday that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz, which the company asserted against Sandoz Inc. and others, is not invalid as indefinite.

  4. July 21, 2015

    Pfizer Gets Partial Win In Sandoz Generic Bladder Drug Row

    A Delaware federal judge ruled Tuesday that Sandoz Inc. infringed two of five patents licensed by Pfizer Inc. protecting the latter's Toviaz overactive bladder treatment, saying the testimony of Pfizer's expert witness was credible and persuasive.

  5. June 24, 2013

    Pfizer Hits Alkem, Sandoz With Suits Over Generic Toviaz

    Pfizer Inc. hit Alkem Laboratories Ltd. and Sandoz Inc. with lawsuits Friday aimed at blocking their recent bids to launch generic versions of Pfizer's Toviaz, a drug used to treat overactive bladders.